tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Polymyositis D017285 1 associated lipids
Scorpion Stings D065008 1 associated lipids
Rotavirus Infections D012400 1 associated lipids
Netherton Syndrome D056770 1 associated lipids
Pseudohypoaldosteronism D011546 1 associated lipids
Dendritic Cell Sarcoma, Interdigitating D054739 1 associated lipids
Thrombotic Microangiopathies D057049 1 associated lipids
Autoimmune Diseases of the Nervous System D020274 1 associated lipids
Lupus Erythematosus, Discoid D008179 1 associated lipids
Lymphocytic Choriomeningitis D008216 1 associated lipids
Erythroplasia D004919 1 associated lipids
Hepatic Veno-Occlusive Disease D006504 1 associated lipids
West Nile Fever D014901 1 associated lipids
Hypoalbuminemia D034141 1 associated lipids
Arm Injuries D001134 1 associated lipids
Intussusception D007443 1 associated lipids
Primary Graft Dysfunction D055031 1 associated lipids
Esophageal Perforation D004939 1 associated lipids
Epididymitis D004823 1 associated lipids
Pruritus Vulvae D011539 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Farid SG et al. Alemtuzumab (Campath-1H)-induced coagulopathy in renal transplantation. 2009 Transplantation pmid:19502974
Shin BH et al. Regulation of anti-HLA antibody-dependent natural killer cell activation by immunosuppressive agents. 2014 Transplantation pmid:24342979
Yoon SH et al. CYP3A and ABCB1 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of tacrolimus and its metabolites (M-I and M-III). 2013 Transplantation pmid:23364483
Cvetkovic M et al. The deleterious effects of long-term cyclosporine A, cyclosporine G, and FK506 on bone mineral metabolism in vivo. 1994 Transplantation pmid:7513912
Nakamura Y et al. Acceptance of islet allografts in the liver of mice by blockade of an inducible costimulator. 2003 Transplantation pmid:12717187
Boukriche Y et al. Severe axonal polyneuropathy after a FK506 overdosage in a lung transplant recipient. 2001 Transplantation pmid:11740402
Hodge G et al. Lymphocytic bronchiolitis is associated with inadequate suppression of blood T-cell granzyme B, IFN-gamma, and TNF-alpha. 2010 Transplantation pmid:20559033
Anderson PO Tacrolimus and breastfeeding. 1998 Transplantation pmid:9539100
Berenguer M et al. Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients. 2010 Transplantation pmid:21068701
Weir MR et al. Long-term Follow-up of Kidney Transplant Recipients in the Spare-the-Nephron-Trial. 2017 Transplantation pmid:26950714
Manez R et al. Rejection and hepatitis in liver transplants. 1994 Transplantation pmid:7517080
Cao W et al. Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis. Inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506. 1995 Transplantation pmid:7532879
Murase N et al. Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. 1990 Transplantation pmid:1696405
Migita K et al. FK506 potentiates steroid-induced T-cell apoptosis. 1997 Transplantation pmid:9371682
Fabrega AJ et al. Enhancement of allograft survival by single intraoperative donor-specific blood transfusion combined with FK506. 1993 Transplantation pmid:7506458
Jain A et al. FK506 and pregnancy in liver transplant patients. 1993 Transplantation pmid:7506459
Sankary HN et al. FK506 treatment in combination with leflunomide in hamster-to-rat heart and liver xenograft transplantation. 1998 Transplantation pmid:9798690
Koh A et al. Supplemental islet infusions restore insulin independence after graft dysfunction in islet transplant recipients. 2010 Transplantation pmid:20145529
Sofi AA et al. Bullous pemphigoid associated with acute renal allograft rejection. 2010 Transplantation pmid:20145531
Butani L et al. Amelioration of tacrolimus-induced nephrotoxicity in rats using juniper oil. 2003 Transplantation pmid:12883183
David-Neto E et al. Longitudinal Pharmacokinetics of Tacrolimus in Elderly Compared With Younger Recipients in the First 6 Months After Renal Transplantation. 2017 Transplantation pmid:27482958
Ciancio G et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimums/mycophenolate versus cyclosporine/sirolimus in renal transplantation: three-year analysis. 2006 Transplantation pmid:16570006
Barten MJ et al. Synergistic effects of sirolimus with cyclosporine and tacrolimus: analysis of immunosuppression on lymphocyte proliferation and activation in rat whole blood. 2004 Transplantation pmid:15114077
Uryuhara K et al. Thymectomy impairs but does not uniformly abrogate long-term acceptance of semi-identical liver allograft in inbred miniature Swine temporarily treated with FK506. 2004 Transplantation pmid:15114080
Gruessner RW et al. Solitary pancreas transplantation for nonuremic patients with labile insulin-dependent diabetes mellitus. 1997 Transplantation pmid:9415558
Pruvot FR and Noel C Comment on "Pregnancy after liver transplantation under tacrolimus" by Jain et al. 1998 Transplantation pmid:9625033
Shackleton CR et al. Lack of correlation between the magnitude of preservation injury and the incidence of acute rejection, need for OKT3, and conversion to FK506 in cyclosporine-treated primary liver allograft recipients. 1995 Transplantation pmid:7570950
Shimada T et al. Lowered blood concentration of tacrolimus and its recovery with changes in expression of CYP3A and P-glycoprotein after high-dose steroid therapy. 2002 Transplantation pmid:12451243
Herlenius G et al. Chronic kidney disease--a common and serious complication after intestinal transplantation. 2008 Transplantation pmid:18622286
Watson MJ et al. Renal function impacts outcomes after intestinal transplantation. 2008 Transplantation pmid:18622288
Glicklich D et al. Chronic renal allograft rejection: no response to mycophenolate mofetil. 1998 Transplantation pmid:9721811
Calandra S Sinus arrest during tacrolimus treatment: was the QT interval prolonged? 1998 Transplantation pmid:9721813
Nakata Y et al. Tacrolimus and myocardial hypertrophy. 2000 Transplantation pmid:10830241
Ji E et al. Combinational effect of intestinal and hepatic CYP3A5 genotypes on tacrolimus pharmacokinetics in recipients of living donor liver transplantation. 2012 Transplantation pmid:22992768
Klein A et al. Impact of a pharmaceutical care program on liver transplant patients' compliance with immunosuppressive medication: a prospective, randomized, controlled trial using electronic monitoring. 2009 Transplantation pmid:19300186
Beckebaum S et al. Predictive factors of outcome in patients transplanted for hepatitis B. 2009 Transplantation pmid:19300191
Mazariegos GV et al. Weaning of immunosuppression in liver transplant recipients. 1997 Transplantation pmid:9020325
Pascual J et al. Authors' reply: cyclosporine A versus tacrolimus in steroid withdrawal strategies. 2011 Transplantation pmid:21336083
Hebert MF et al. Interpreting tacrolimus concentrations during pregnancy and postpartum. 2013 Transplantation pmid:23274970
Fujishiro J et al. Immunologic benefits of longer graft in rat allogenic small bowel transplantation. 2005 Transplantation pmid:15665767
Farley DE et al. The effect of two new immunosuppressive agents, FK506 and didemnin B, in murine pregnancy. 1991 Transplantation pmid:1713360
Thai NL et al. Pancreas transplantation under alemtuzumab (Campath-1H) and tacrolimus: Correlation between low T-cell responses and infection. 2006 Transplantation pmid:17198253
Hricik DE et al. Outcomes of African American kidney transplant recipients treated with sirolimus, tacrolimus, and corticosteroids. 2002 Transplantation pmid:12151730
Kainz A et al. Review of the course and outcome of 100 pregnancies in 84 women treated with tacrolimus. 2000 Transplantation pmid:11152103
Krähenbühl S et al. Serious interaction between mibefradil and tacrolimus. 1998 Transplantation pmid:9808502
Tsamandas AC et al. Central venulitis in the allograft liver: a clinicopathologic study. 1997 Transplantation pmid:9256183
Aisa Y et al. Effects of immunosuppressive agents on magnesium metabolism early after allogeneic hematopoietic stem cell transplantation. 2005 Transplantation pmid:16278584
Tanaka J et al. The immunosuppressive agent FK506 enhances the cytolytic activity of inhibitory natural killer cell receptor (CD94/NKG2A)-expressing CD8 T cells. 2005 Transplantation pmid:16378079
Dharancy S et al. Elevated interleukin-4 expression in severe recurrent hepatitis C virus after liver transplantation. 2007 Transplantation pmid:17460561
Vadivel N et al. Tacrolimus dose in black renal transplant recipients. 2007 Transplantation pmid:17460575